anti-TNF agents
Assessing risk of liver enzyme elevation in patients with immune mediated diseases and different hepatitis B virus serostatus receiving anti TNF agents: a nested case control study
... ing anti-TNF agents has been reported in individual cases and small clinic-based cohorts, the risk esti- mates provided by such studies are imprecise [1, 6– 11]; for example, the risk may be ...
9
Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents
... excess TNF, nor, indeed how extracellular cerebral glutamate reaches toxic levels in these ...excessive TNF harms the central nervous system largely through causing extracellular glutamate to accumulate to ...
16
Pain experience in children with juvenile idiopathic arthritis treated with anti-TNF agents compared to non-biologic standard treatment
... with anti-TNF agents, and to compare the pain scores with pain reported by children receiving standard ...the anti-TNF group have most often started anti-TNF treatment ...
8
Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates
... in anti-TNF access criteria [4] are routinely collected in clinical practice for multiple ...the anti-TNF access criteria in place in France [19] and numerous other set- ...for ...
13
Do anti TNF agents have equal efficacy in patients with rheumatoid arthritis?
... infliximab does not bind lymphotoxin-α [38]: it binds both the monomeric and trimeric forms of the inflammatory cytokine TNF, forming a stable molecular complex with both molecular species. Infliximab must be ...
9
Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management
... of anti-TNF- a treatment was 26.6 months. According to the definitions approved by the American Association for the Study of Liver Diseases, five out of seven patients were HBeAg− CHB carriers, while the ...
6
Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
... with rheumatologists. Each participating physician was interviewed based on a structured questionnaire designed to collect information regarding the demographics of managed patients and the followed treatment patterns. ...
9
Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis
... of anti-TNF treatment was ...one anti-TNF agent was given in ...different anti-TNF agents for the duration of ...one anti-TNF agent was the only factor ...
6
Golimumab for the treatment of ulcerative colitis
... these agents, especially when antibodies against the given biological have ...another anti-TNF agent is generally ...novel anti-TNF agents for UC patients in whom therapy with ...
7
Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study
... In conclusion, our results show a linear association between adherence to anti-TNF agents and loss of response. Additionally, adherence is substantially lower in patients treated with adali- mumab, ...
7
Abstract
... with anti−TNF agents, the experience with infliximab suggests a significant benefit in rapidly reducing inflammation and pos− sible long−term effects on proteinuria and hema− turia, despite the ...
7
What Is the Personal Experience of IBD Patients about Their Anti TNF Alpha Therapy?
... biological agents, these treatment goals can now be ...used anti-TNF- α bio- logical therapies licensed for the treatment of IBD (CD and/or UC) in ...two anti-TNF agents are ...
12
Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions
... of anti-TNF agents, such as adalimumab, in juvenile idiopathic arthritis has made significant impact on the resolution of clinical symptoms, disease activity on physical examination, and radiographic ...
9
Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis
... of 40 mg every 2 weeks. Three patients who would not have been compliant with adalimumab, received intrave- nous infliximab at the dose of 5 mg/kg at baseline, after 2 and 6 weeks, and then every 6 to 8 weeks. Before ...
8
Salivary Antioxidants and Metalloproteinases in Juvenile Idiopathic Arthritis
... receiving anti-TNF therapy (5 with Infliximab, 9 with ...of anti-oxidant status, metalloproteinases (MMPs) and ...with anti-TNF ...without anti-TNF treat- ment by ...with ...
7
Incidences of Serious Infections and Tuberculosis among Patients Receiving Anti Tumor Necrosis Factor α Therapy
... receiving anti-TNF-α therapy were analyzed. Before evaluating TB due to anti-TNF-α therapy, we reviewed the rates of latent TB infection diagnosed by a latent screening ...of ...
7
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
... non-steroidal anti-inflammatory drugs (NSAIDs), or an intol- erance to them, and active or documented history of plaque psoriasis or psoriatic nail ...used anti-TNF agents could enrol if they ...
8
NOVEL ANTI-ARRHYHTMIC AGENTS
... class Ia class 1b class Ic -Quinidine -Phenytoin - Flecainide -Disopyramide -Lignocaine - Encainide, -Procainamide -Mexiletine - Propafenone NOVEL CLASS-I AGENTS: ...
23
NATURAL ANTI-PLATELET AGENTS
... current anti-platelet drugs (aspirin, ticlopidine, dypiridamol and clopidogrel) is still ...new anti-platelet agents is a current matter for research ...
8
Boron Pleuromutilins as Anti Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis
... B. malayi SCID Mouse Infection Models. A B. malayi SCID mouse infection model for anti-Wolbachia drug screening was used as previously described 34,51−53 In brief, B. malayi L3 larvae were generated by membrane ...
20